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Exquisite control of cholesterol synthesis is crucial
for maintaining homeostasis of this vital yet poten-
tially toxic lipid. Squalene monooxygenase (SM)
catalyzes the first oxygenation step in cholesterol
synthesis, acting on squalene before cyclization
into the basic steroid structure. Using model cell
systems, we found that cholesterol caused the accu-
mulation of the substrate squalene, suggesting that
SM may serve as a flux-controlling enzyme beyond
3-hydroxy-3-methylglutaryl-coenzyme A reductase
(HMGR, considered as rate limiting). Cholesterol
accelerated the proteasomal degradation of SM
which required the N-terminal domain, partially
conserved in vertebrates but not in lower organisms.
Unlike HMGR, SM degradation is not mediated
by Insig, 24,25-dihydrolanosterol, or side-chain
oxysterols, but rather by cholesterol itself. Impor-
tantly, SM’s N-terminal domain conferred choles-
terol-regulated turnover on heterologous fusion
proteins. Furthermore, proteasomal inhibition almost
totally eliminated squalene accumulation, high-
lighting the importance of this degradation mecha-
nism for the control of SM and suggesting this as
a possible control point in cholesterol synthesis.
INTRODUCTION
Cholesterol is a vital lipid in animals, but also can be toxic
in excess. Consequently, elaborate homeostatic mechanisms
have evolved, with exquisite control of cholesterol levels occur-
ring at multiple levels within the cell (Goldstein et al., 2006).
Research into the regulation of cholesterol synthesis has
centered on 3-hydroxy-3-methylglutaryl-coenzyme A reductase
(HMGR). It catalyzes a major ‘‘rate-limiting’’ step or control point
in cholesterol synthesis (Rodwell et al., 1976), yielding mevalo-
nate, and is the target of the statin class of drugs used to treat
hypercholesterolemia. HMGR is regulated by several mecha-
nisms, notably by the transcription factor SREBP-2 (sterol
regulatory element binding protein-2), and through proteasomal
degradation via Insig binding to its sterol-sensing domain260 Cell Metabolism 13, 260–273, March 2, 2011 ª2011 Elsevier Inc.(DeBose-Boyd, 2008). In contrast, relatively little is known
about the regulatory role and control of other enzymes in the
pathway, although most are known SREBP-2 target genes
(Horton et al., 2003).
One such enzyme is squalene monooxygenase (SM), formerly
squalene epoxidase (EC 1.14.99.7). SM is a microsomal flavin
monooxygenase (Yamamoto and Bloch, 1970) that catalyzes
the first oxygenation step in cholesterol synthesis, the conver-
sion of squalene to the nonsterol precursor for lanosterol, 2,3
(S)-monooxidosqualene (MOS) (Figure S1A available online).
SM is important clinically as the target of fungicides such as ter-
binafine (Chugh et al., 2003). In addition, a number of natural
compounds proposed to reduce serum cholesterol levels in
humans inhibit this enzyme, such as polyphenols in green tea,
resveratrol in wine, and garlic extract (Abe et al., 2000; Gupta
and Porter, 2001). Although not widely appreciated, SM has
been proposed to be a second rate-limiting enzyme in choles-
terol synthesis (Gonzalez et al., 1979; Hidaka et al., 1990). The
precursor squalene accumulates when Chinese hamster ovary
(CHO) cells (Eilenberg and Shechter, 1984), human fibroblasts
(Brown andGoldstein, 1980), rat hepatoma cells, and renal carci-
noma cells (Gonzalez et al., 1979) are incubated with radiola-
beled mevalonate and exogenous sterols. Similar accumulation
has also been observed using rat and dog kidney slices (Raskin
and Siperstein, 1974). Furthermore, the concept that SM may
be a largely overlooked control point in cholesterol synthesis is
suggested by its much lower specific activity in liver cells
compared to that of HMGR (Hidaka et al., 1990).
As an SREBP-2 target, SMexpression ismodulated by sterols,
increasing under lipid-depleted conditions (Hidaka et al., 1990;
Nagai et al., 2002). Here, we report that SM is also posttransla-
tionally regulated by cholesterol-dependent proteasomal
degradation. Inhibition of the proteasome prevents squalene
accumulation in response to cholesterol treatment, suggesting
that this mechanism constitutes a possible control point in
cholesterol synthesis beyond HMGR.RESULTS
Cholesterol Treatment Causes Squalene to Accumulate
A key observation that highlights the rate-limiting activity of SM
is squalene accumulation when cholesterol levels are high
(Brown and Goldstein, 1980; Eilenberg and Shechter, 1984;
Gonzalez et al., 1979). These experiments were conducted
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We labeled CHO-7 cells for 4 hr with [14C]-acetate, which feeds
into the beginning of the cholesterol biosynthetic pathway.
CHO-7 cells were chosen because they can be maintained in
lipoprotein-deficient serum (LPDS) (Metherall et al., 1989), which
offers considerable flexibility in manipulating cholesterol levels.
Importantly, we found that treatment of CHO-7 cells with sterols
and [14C]-acetate also led to the accumulation of [14C]-squalene
(Figure 1A). This band was absent upon inhibition of squalene
synthase (lane 1) and accumulated when SM was inhibited
(lane 2). The most striking squalene accumulation resulted
from addition of cholesterol complexed with methyl-b-cyclodex-
trin (Chol/CD, lane 5), followed by low-density lipoprotein (LDL)
(lane 4), and then the oxysterol 25-hydroxycholesterol (25HC)
(lane 6). Thus, in this system, cholesterol treatment induces
squalene accumulation, raising the possibility of a rate-limiting
step after HMGR involving SM.
Experiments examining cholesterol homeostasis commonly
use statin pretreatment, which reduces cellular cholesterol
status and increases the expression of cholesterogenic genes
(Wong et al., 2008). Under these conditions, HMGR activity
may be increased sufficiently such that it is no longer rate-
limiting, producing a bottleneck downstream at SM. To address
this possibility, acute cholesterol treatment (Chol/CD and LDL)
was repeated for CHO-7 cells maintained in full serum without
statin pretreatment (Figure 1B). Squalene accumulatedmarkedly
when cells were grown in full serum (lane 4), albeit to a lesser
extent than seen for LPDS (lane 2). Squalene accumulation
was also observed with or without the statin pretreatment (Fig-
ure S1B), that is, whether or not HMGR was first inhibited.
Furthermore, if cholesterol treatment were to inactivate HMGR
faster than SM, then accumulation of squalene (occurring after
HMGR) would not be observed. Thus, cholesterol treatment
caused squalene to accumulate under a variety of culturing
conditions, suggesting that altered activity of earlier enzymes
in the pathway, such as HMGR, is insufficient to explain the
squalene accumulation. Furthermore, the effect is not restricted
to CHO-7 cells (Figure 1C): a cholesterol-dependent increase in
squalene accumulation was also seen in three human cell-lines
of hepatic (HepG2), neuronal [BE(2)C], and renal (HEK293) origin,
as well as in primary human fibroblasts (Fb).
When examined over time, cholesterol treatment led to the
progressive accumulation of squalene and decreased de novo
cholesterol synthesis (Figure 1D), most notably after 4 hr (lane
5), but also as early as 2 hr (lane 3). In the absence of exogenous
cholesterol, the levels of newly synthesized cholesterol were
relatively constant, with no observed squalene. These results
suggest that SM becomes rate-limiting due to an acute choles-
terol-dependent regulatory mechanism.
To uncover this mechanism, we first examined transcriptional
regulation using quantitative (real-time) PCR and compared the
messenger RNA (mRNA) levels of SQLE (SM) to that of HMGCR
(HMGR). In the absence of added cholesterol, the mRNA levels
of both genes were constant and remained unaffected over
16 hr (Figure 1E). The addition of cholesterol caused a decrease
in expression levels of both genes with similar kinetics and
magnitude. Therefore, there is dissociation of mRNA levels
from flux through the pathway, suggesting posttranscriptional
regulation of SM.CeCholesterol-Dependent Posttranscriptional
Regulation of SM
To exclude transcriptional regulation, we utilized SRD-1 cells,
a mutant line of CHO cells which exhibit sterol-independent
expression of SREBP-2 target genes (Yang et al., 1994). These
cells overexpress a truncated form of SREBP-2, bypassing the
sterol-regulated proteolytic step, leading to constant transcrip-
tional activation regardless of sterol levels. Thus, mRNA levels
of HMGCR and SQLE were similarly unaffected by cholesterol
addition (Figure 2A). Nevertheless, cholesterol-dependent squa-
lene accumulation was still evident in SRD-1 cells (Figure 2B).
This is consistent with SM being posttranscriptionally regulated
by cholesterol, which may impact on the control of cholesterol
synthesis.
Cholesterol-Dependent Degradation of SM
One explanation for the accumulation of squalene is that choles-
terol also acts posttranslationally, accelerating the degradation
of SM.We investigated this possibility in SRD-1 cells (Figure 3A).
Chol/CD caused a reduction in endogenous SM protein from
4 hr, with negligible levels by 8 hr (lane 7). This effect was not
observed when cells were treated with methyl-b-cyclodextrin
(CD) without cholesterol (Figure 3B, lane 3). Protein synthesis
was inhibited with cycloheximide (CHX) during cholesterol treat-
ment, showing that the regulation was posttranslational, through
degradation of SM. This cholesterol-mediated degradation of
SM was on a comparably acute timescale to squalene accumu-
lation (cf. Figure 2B). Overall, addition of cholesterol increased
SM turnover several-fold, with the estimated half-life decreasing
from14 hr to4 hr. Exogenous cholesterol derived solely from
serum also appeared to promote degradation (Figure S2): SM
protein levels were lower in full serum (NCS) compared with
cholesterol-depleted serum (LPDS) after 8 hr.
Sterol Specificity—Cholesterol as the Principal
Degradative Signal
Next, we examined whether endogenously synthesized sterols
could regulate SM. We pretreated cells for 16 hr with a statin
to inhibit sterol synthesis, lowering cholesterol levels and upre-
gulating SREBP-2 target genes. The removal of the statin from
the media then allows increased sterol synthesis due to the
higher level of biosynthetic enzymes (Wong et al., 2008). Total
cellular cholesterol at 8 hr increased by 20% when statin was
withdrawn from SRD-1 cells (an increase of 7 mg/mg from
34 mg/mg cell protein). This newly synthesized sterol was suffi-
cient to accelerate the degradation of SM (Figure 4A). Inhibiting
later steps in themevalonate pathway, at SM and lanosterol syn-
thase (the first sterol generating enzyme), preserved SM protein
levels to the same extent as statin (Figure 4B, lanes 1, 3, and 5),
indicating that the degradative signal is a sterol.
To examine the sterol specificity of this potential regulatory
mechanism, we tested the ability of a selection of sterol pathway
intermediates and oxysterols to cause degradation of ectopic,
human SM. Consistent with our results for endogenous hamster
protein, there was a cholesterol-dependent reduction in human
SM (with expression in CHO-7 cells driven by a thymidine kinase
[TK] promoter) (Figure 4C, lanes 3 and 4). In contrast, a construct
with a higher expression cytomegalovirus (CMV) promoter did
not show clear sterol regulation (lanes 7 and 8).ll Metabolism 13, 260–273, March 2, 2011 ª2011 Elsevier Inc. 261
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Figure 2. Cholesterol Treatment Causes Squalene to Accumulate in SRD-1 Cells, Independent of Transcriptional Regulation
(A) Cells were treated as in Figure 1E (n = 3, each performed in triplicate, ± SEM).
(B) Cells were treated and data presented as in Figure 1D (n = 4, ± SEM).
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or more additional oxygen-containing groups on the carbon
backbone of cholesterol or related sterols (Figure 4D). A concen-
tration of 25HC (1 mg/ml) commonly used to inhibit SREBP pro-
cessing (Adams et al., 2004) did not destabilize SM, nor did
24,25EC (1 mg/ml), a physiological regulator of cholesterolFigure 1. Cholesterol Treatment Causes Squalene to Accumulate in V
(A, C, and D) Cells were statin pretreated overnight, treated with test agents as ind
squalene accumulation. Representative phosphorimages are shown.
(A) CHO-7 cells were treated and labeled with [14C]-acetate in medium A with
SM inhibitor (SMi, 10 mM), LDL (50 mg/ml), cholesterol complexed with meth
(25HC, 1 mg/ml). [14C]-Squalene accumulation was expressed relative to the ma
(B) After 16 hr of growth in either LPDS (medium A) or NCS (medium C) without st
4 hr with or without Chol/CD (20 mg/ml; top panel) or LDL (50 mg/ml; bottom pan
(C) Cells in medium E (HepG2) or medium H [BE(2)C, HEK293, and fibroblasts
(20 mg/ml) for 4 hr (n = 2).
(D) Statin pretreated CHO-7 cells were treated in medium B with or without Chol
treatment 2 hr prior to harvesting. Relative accumulation was calculated so that [
contained within the symbols (n = 6).
(E) CHO-7 cells were treated as in (D) without radiolabeling and mRNA levels for
performed in triplicate, ± SEM).
See also Figure S1.
Cesynthesis (Wong et al., 2008) (Figure 4E). A range of sterols
and oxysterols were delivered complexed in methyl-b-cyclodex-
trin at the same concentration as cholesterol (20 mg/ml; Figures
4F and 4G). Treatment with the side-chain oxysterols 24,25EC,
25HC, and 27-hydroxycholesterol (27HC) again had no effect
on SM protein levels (Figure 4F, lanes 6–8), in contrast to whatarious Cells
icated, labeled with [14C]-acetate, and assayed for [14C]-cholesterol and [14C]-
the following test agents for 4 hr: squalene synthase inhibitor (SSi, 150 mM),
yl-b-cyclodextrin (Chol/CD, 20 mg cholesterol/ml), or 25-hydroxycholesterol
ximal condition (Chol/CD), which was set to 1 (n = 5, +SEM).
atin pretreatment, CHO-7 cells were labeled with [14C]-acetate, and treated for
el) (each n = 2).
(Fbs)] were labeled with [14C]-acetate, and treated with or without Chol/CD
/CD (20 mg/ml) as indicated and labeled with [14C]-acetate in medium A during
14C]-squalene + [14C]-cholesterol = 1 at each time point. Error bars (±SEM) are
hamster SM and HMGR determined by quantitative real-time PCR (n = 3, each
ll Metabolism 13, 260–273, March 2, 2011 ª2011 Elsevier Inc. 263
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Figure 3. Cholesterol Treatment Reduces SM Protein Levels Posttranslationally in SRD-1 Cells
SRD-1 cells were statin pretreated overnight and treated as indicated in medium A containing cycloheximide (10 mg/ml) and Chol/CD (20 mg/ml) (A) or additionally
withmethyl-b-cyclodextrin (CD) (B) for 8 hr. Cell lysates were assayed for SMby immunoblotting (n = 3, ± SEM for A). A second band (50 kDa) sometimes evident
in the immunoblots of the endogenous protein, likely reflects partial degradation (Sakakibara et al., 1995), but not an intermediate in sterol regulated degradation,
since it is unaffected by cholesterol treatment. See also Figure S2.
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However, the steroid-ring oxysterols 7a-hydroxycholesterol
(7aHC), 7b-hydroxcholesterol (7bHC), 7-ketocholesterol (7KC),
and synthetic 19-hydroxycholesterol (19HC) induced degrada-
tion (Figure 4F, lanes 2–5). Significantly, the likely cellular
concentration of these oxysterols would be dramatically supra-
physiological and the most potent oxysterol tested, 19HC, is
not found in nature (Brown and Jessup, 1999; Brown et al.,
1997). For the pathway sterols, the major methyl-sterol interme-
diates lanosterol and 24,25-dihydrolanosterol (24,25DHL)—the
latter of which also accelerates degradation of HMGR (Lange
et al., 2008; Song et al., 2005)—had no effect on SM (Figure 4G,
lanes 7 and 8). 7-Dehydrocholesterol (7DHC) and lathosterol
with double bonds on the steroid ring also did not reduce SM
protein levels (lanes 5 and 6), whereas desmosterol which differs
only by a double bond on the side chain was as effective
as cholesterol (lane 4 versus lane 3). Thus, due to its much
greater relative abundance compared to 7-oxygenated sterols
(Brown and Jessup, 1999) or desmosterol (Yang et al., 2006),
cholesterol itself appears to be the primary signal that mediates
accelerated turnover of SM. The inverse curvilinear relationship
between cholesterol and SM protein levels suggests the pres-
ence of a threshold required to trigger rapid degradation,
approximately 15–20 mg total cholesterol/mg total protein in
CHO-7 cells (Figure 4H). This threshold is close to the basal
cholesterol value of 15 mg/mg protein observed in full serum
without statin pretreatment (Figure S3A), consistent with a
physiological feedback role for SM degradation in control of
cholesterol synthesis.
Cholesterol-Dependent Degradation of SM
Is Proteasomal
Since SM is associated with the endoplasmic reticulum (ER), and
the fate of many ER-bound proteins is destruction by the protea-
some (Hampton, 2002), it is likely that the cholesterol-dependent
degradation of SM is proteasomal. In support of this, a range of264 Cell Metabolism 13, 260–273, March 2, 2011 ª2011 Elsevier Inc.proteasomal inhibitors (ALLN, MG132, and lactacystin) pre-
served endogenous SM protein levels (Figure S4A). On the
contrary, a lysosomal inhibitor had no effect (Figure S4B). Over
a period of 8 hr, cholesterol-mediated degradation of the enzyme
could be prevented with the proteasomal inhibitor MG132 (Fig-
ure 5A). As observed with endogenous hamster SM, the choles-
terol-dependent reduction in ectopic human enzyme was
rescued by the addition of MG132 (Figure 5B, lane 2 versus
lane 4). Alternatively, glycine-alanine repeats (GAr) from Epstein-
Barr virus nuclear antigen-1 were added to the ends of the
human protein to provide resistance to proteasomal degradation
(Sharipo et al., 1998). A single 30 amino acid repeat at the C
terminus slightly increased protein levels (Figure 5C, lane 3
versus lane 1), whereas repeats on both the N and C termini
blunted cholesterol-dependent degradation (lanes 5 and 6).
Furthermore, in coexpression experiments with HA-tagged
ubiquitin, human SM was polyubiquitinated in the presence
of MG132, which was greater in the presence of cholesterol
(Figure 5D, lane 4 versus lane 3). Thus, SM is degraded by the
ubiquitin-proteasome system.
Importantly, in SRD-1 cells, proteasomal inhibition dramati-
cally reduced the accumulation of squalene after 4 hr of choles-
terol treatment and increased cholesterol synthesis from acetate
(Figure 5E, lane 4 versus lane 3). The same effect was also
observed using radiolabeled mevalonate in both SRD-1 and
CHO-7 cells (Figures 5G and 5F, respectively), thus bypassing
HMGR. This is consistent with the cholesterol-dependent pro-
teasomal degradation of SM having functional consequences,
by contributing to the squalene accumulation observed.
Insig and Scap Are Not Required for the
Cholesterol-Dependent Degradation of SM
Sterol-dependent degradation of HMGR requires its sterol-
sensing domain, which binds to the Insig retention protein,
which in turn brings a ubiquitin ligase into contact with HMGR
(DeBose-Boyd, 2008). To determine whether Insig is required
Cell Metabolism
Regulated Degradation of Squalene Monooxygenasefor degradation of SM, we observed lipid synthesis and SM
turnover in SRD-15 cells. These mutant CHO cells are deficient
in Insig, with no functional Insig-1 isoform, and an extremely
low level of Insig-2 (Lee et al., 2005). When SRD-15 cells were
treated with cholesterol, squalene still accumulated (Figure 6A)
and protein degradation was still observed for both endogenous
SM (Figure 6B, lane 2) and ectopic human SM (Figure 6C, left
panel, lane 4). Cholesterol-dependent degradation of SM also
occurred in SRD-13A cells (Rawson et al., 1999), mutant CHO
cells which lack the cholesterol-sensing protein Scap and
consequently do not have a functional SREBP pathway (Fig-
ure 6C, right panel, lane 2). Thus, Insig and Scap are not required
for degradation of SM. Furthermore, if additional regulatory
machinery is necessary, then the genes are unlikely to be strict
SREBP-2 targets.
Cholesterol-Dependent Proteasomal Degradation
of SM Requires Its N-Terminal Domain
The N terminus of SM, encoded by the first exon, is partially
conserved in vertebrates but lacking in lower organisms (Fig-
ure 7A and Figure S5A). In addition, a recombinant truncated
rat enzymemissing the first 99 residues retains full activity (Saka-
kibara et al., 1995). This led us to suspect that the vertebrate
N-terminal region is a structurally and functionally distinct domain
that may play a role in posttranscriptional regulation. We con-
structed a corresponding human version that is missing the
N-terminal region [D(W2-K100); Figure 7B], and examined
its response to cholesterol treatment (Figure 7C). After cell frac-
tionation, the truncated enzyme remains associated with the
membrane fraction (Figure S5B, lane 5), consistent with wild-
type localization. However, unlike full-length SM (WT, Figure 7C,
lane 2 versus lane 1), turnover of this deletion construct was unaf-
fected by cholesterol (lane 5 versus lane 4), and levels were
further increased by addition of MG132 (lane 6 versus lane 4).
We then determined whether this lack of cholesterol-regula-
tion of the deletion construct has functional consequences by
acutely labeling transfected cells with [14C]-acetate. Importantly,
we observed that MOS, the product of SM, accumulates
preferentially in cholesterol-treated cells transfected with the
N-terminal deletion construct compared to full-length SM (Fig-
ure 7D, lane 4 versus lane 2). Accordingly, densitometric analysis
showed that the squalene precursor to MOS product ratio was
30%–40% lower in the cholesterol-treated cells transfected
with the truncated construct, in keeping with the failure of
cholesterol to accelerate degradation of this variant.
We next prepared a complementary construct of the first 100
amino acids of epitope-tagged human SM, but it failed to
express (data not shown). This may be due to the extremely
hydrophobic character of this region, previously proposed to
contain transmembrane domains (Ono, 2002; Sakakibara et al.,
1995). However, protease protection experiments conducted
in our laboratory suggested that it does not contain membrane
spanning a helices. For example, an N-terminal Myc or internal
FLAG epitope tag within this sequence were degraded when
protease-impermeable membrane vesicles were treated with
trypsin (data not shown).
To assist folding or solubilization and enable expression, we
fused the first 100 amino acids (N100) to green fluorescent
protein (N100-GFP) or glutathione S-transferase (N100-GST)Ceunder the control of the TK promoter (Figure 7B). Despite the
apparent absence ofmembrane spanning a helices, the chimeric
fusion protein was still membrane associated (Figure S5B, right
panel, lane 2). Importantly, turnover of both heterologous fusion
constructs was robustly regulated by cholesterol (Figure 7E,
lane 4 versus lane 3; Figure S5E, lane 2 versus lane 1), whereas
expression of either GFPorGST alonewas unaffected by choles-
terol treatment (data not shown).When the full-length protein and
truncated chimera were co-transfected, cholesterol-dependent
turnover of each was also unaffected (Figure 7E, lane 6 versus
lane 5). This was surprising in light of themarked blunting of regu-
lation seen for theCMVsystemearlier, because expression of the
TK-driven truncated fusion protein (N100-GFP) wasmuch higher
than the full-length non-fusion protein (data not shown).
A pulse-chase approach, which permits the study of protein
degradation without the use of cycloheximide, confirmed that
Chol/CD treatment accelerates degradation of the N100-GST
(Figure 7F) and suggests a comparable half-life (3 hr) to that
seen in the cycloheximide-containing studies on full-length
endogenous SM (4 hr in Figures 3A and 5A). Without added
cholesterol, the N100-GST appeared remarkably stable over
the 8 hr. Cholesterol began to degrade this truncated version
of SM by 2 hr (Figure 7F), in line with the timing observed for
squalene accumulation (Figures 1D and 2B). This pulse-chase
approach was not possible for endogenous SM due to lack of
an appropriate antibody for immunoprecipitation.
Coexpression of a chain-terminating K48R ubiquitin mutant
through fusion to N100-GFP blunted cholesterol-dependent
degradation and increased SM protein levels compared to
wild-type ubiquitin (Figure S5F), again implicating the ubiquitin-
proteasome system. Moreover, GST pull-down of the
N100-GST chimera coexpressed with HA-tagged ubiquitin
revealed clear cholesterol-dependent polyubiquitination (Fig-
ure 7G, lane 1 versus lane 2), which was observed as early as
one hour after cholesterol treatment (Figure S5G).
Together, these data suggest that the N-terminal region forms
a regulatory domain, which is necessary and sufficient for post-
translational regulation of SM by the proteasome, and which in
turn may help to regulate flux through the cholesterol biosyn-
thetic pathway.
DISCUSSION
Cholesterol synthesis is controlled at multiple levels, including
transcriptionally by the SREBPs (Goldstein et al., 2006), and
posttranscriptionally, notably at HMGR (DeBose-Boyd, 2008).
Here, we present evidence that cholesterol can stimulate with
considerable specificity the proteasomal degradation of SM,
a neglected enzyme beyond HMGR. Consistent with this,
cholesterol treatment caused the nontoxic isoprenoid squalene
to accumulate in a variety of cell lines (Figure 1), preceding tran-
scriptional downregulation of SM. Indeed, cholesterol-depen-
dent squalene accumulation was also observed in mutant cells
lacking transcriptional regulation by SREBP-2 (Figure 2). At the
posttranslational level, this was accompanied by a reduction in
endogenous SM protein levels (Figure 3). In an example of
end-product inhibition, turnover was accelerated by cholesterol
itself, rather than methylated sterols or side-chain oxysterols
(Figure 4). Cholesterol-dependent degradation of SM alsoll Metabolism 13, 260–273, March 2, 2011 ª2011 Elsevier Inc. 265
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Regulated Degradation of Squalene Monooxygenaserequired the ubiquitin-proteasome system: protein levels were
rescued through proteasomal inhibition with MG132, and poly-
ubiquitination increased on cholesterol treatment (Figure 5).
This mechanism did not require Insig or Scap (Figure 6) but
was mediated by the N-terminal region of human SM, which
also conferred sterol-regulated turnover on heterologous fusion
proteins (Figure 7). Importantly, MG132 reversed the accumula-
tion of squalene, suggesting that accelerated proteasomal
degradation of SM may help to acutely control flux through the
cholesterol biosynthetic pathway.
Clearly, while this mechanism may be a second example of
regulated degradation for the control of cholesterol synthesis,
it is distinct from the well-characterized ER-associated degra-
dation of HMGR: SM lacks the five transmembrane sterol-
sensing domain and its degradation is not mediated by Insig,
24,25-dihydrolanosterol, or side-chain oxysterols such as
27HC. Indeed, the sterol specificity of SM degradation is also
strikingly different for that previously shown to inhibit SREBP
processing, and/or bind to Scap or Insig (summarized in
Figure S3B).
What might be the evolutionary advantage of having an addi-
tional posttranslational control point for regulating cholesterol
synthesis beyond HMGR? Transcriptional downregulation of
the SREBP pathway is relatively slow, with mRNA levels of target
genes only appreciably decreasing hours after treatment (Fig-
ure 1E), potentially leaving active enzyme with a relatively long
half-life. More rapid shutdown of cholesterol synthesis requires
posttranscriptional control, such as the well-documented
proteasome-mediated degradation of HMGR (DeBose-Boyd,
2008). However, HMGR activity can vary widely (DeBose-
Boyd, 2008), such that sterol synthesis could be difficult to
dampen in a timely manner. Moreover, some HMGR activity is
needed for isoprenoid production (Brown and Goldstein, 1980).
In contrast, SM appears to have much lower activity than
HMGR (Hidaka et al., 1990) and is committed to sterol produc-
tion, making it suitable for rapid modulation of the cholesterol
biosynthetic pathway independently from isoprenoid synthesis.
We propose a model whereby the mevalonate pathway is
controlled rapidly and segmentally at HMGR and SM (Figure 7H).
One situation in which this could be useful would be to respond
to a sudden influx of exogenous cholesterol while the demand for
isoprenoids such as farnesol or geranylgeraniol remains high.
This argument is consistent with the observation that the physi-
ologically relevant cholesterol molecule itself appears to be the
major signal for SM degradation (Figure 4).Figure 4. Degradation of SM Is Accelerated by Cholesterol Rather Tha
(A and B) SRD-1 cells were statin pretreated overnight and treated as indicated i
5 mM, thus identical to medium B), SM inhibitor (SMi, 10 mM), lanosterol synthase
SM by immunoblotting (n = 4, ± SEM for A).
(D) Cholesterol structure with carbons numbered.
(C and E–H) CHO-7 cells were transfected with 1 mg empty vector (EV), plasmid en
night statin pretreatment, CHO-7 cells were treated for 8 hr in medium B containin
as indicated), 24(S),25-epoxycholesterol (24,25EC, 1 mg/ml), or 25-hydroxycholes
CD complexed with the sterols (20 mg/ml) 7a-hydroxycholesterol (7aHC), 7b-hydro
24,25EC, 25HC, 27-hydroxycholesterol (27HC), cholesterol, desmosterol, 7-de
lanosterol (F and G). SM-V5 protein was analyzed by immunoblotting (each n = 4
(H) CHO-7 cells were transfected and treated as above, except with varying conce
were measured in parallel experiments (n = 3). The error bars (±SEM) presented
See also Figure S3.
CeTo begin delineating the mechanism of accelerated degrada-
tion of SM, we hypothesized that the N terminus was involved,
based on its lack of requirement for catalytic activity (Sakakibara
et al., 1995) and on its evolutionary conservation (Figure 7A).
This region is particularly well-conserved between birds and
mammals, suggesting that this mechanism may have evolved
to assist cholesterol regulation in higher animals. Indeed, we
showed that the first 100 amino acids (comprising 17% of the
protein) was sufficient to mediate cholesterol-regulated turnover
of GST or GFP (Figure 7), when GFP alone for example is other-
wise remarkably stable (Corish and Tyler-Smith, 1999). Although
the membrane topology of SM is currently unknown, our prelim-
inary investigations have determined that the hydrophobic
N-terminal domain is sufficient but not necessary for membrane
association (Figure S5B). This region contains the short
sequences ‘‘YFY’’ and ‘‘LGIA’’ in close proximity, near-identical
to motifs found in transmembrane helices of the sterol-sensing
domain of HMGR and Scap, shown to be functionally important
for Insig binding (Sever et al., 2003; Yabe et al., 2002; Yang et al.,
2002). The YIYF peptide has also been suggested to recruit
cholesterol on the basis of phase transition experiments (Epand,
2006). However, mutation of the tyrosines to serine or the leucine
to alanine did not abolish regulation, although they appeared to
destabilize the protein (Figure S5C, lanes 3 and 4 of each panel).
It is not known whether regulated degradation requires direct
binding of cholesterol to the N terminus. Mutation of a single
tyrosine from a further motif, fulfilling the CRAC cholesterol
binding consensus sequence (Epand, 2006), also had no effect
on regulation (Figure S5C, left panel, lanes 5 and 6). Furthermore,
it is not known whether regulated degradation requires a confor-
mational change mediated by altered membrane structure or
requires a second sensing protein. The blunted regulation
seen for the CMV-driven expression vector (Figure 4C and
data not shown) hints at the presence of additional regulatory
proteins. By contrast, competition for a limiting factor(s) did not
appear to occur when we cotransfected full-length SM and the
massively overexpressed N100-GFP fusion protein (Figure 7E).
Thus, this question remains an area of uncertainty.
Our preliminary experiments using protease protection are
consistent with the N-terminal domain being accessible to
the cytoplasmic ubiquitin-proteasome system. However, our
numerous attempts at identifying an ubiquitination site for SM
using site-directed mutagenesis have been unsuccessful to
date. This involved mutating groups of lysines to arginine,
including selected conserved residues (Figure S5D), or all fromn Side-Chain Oxysterols
n medium A containing cycloheximide (10 mg/ml) and either statin (compactin,
inhibitor (LSi, 10 mM), and/or Chol/CD (20 mg/ml). Cell lysates were assayed for
coding human SM constructs as indicated (C) or pTK-SM-V5 (E–H). After over-
g cycloheximide (10 mg/ml) with or without the following: Chol/CD (20 mg/ml or
terol (25HC, 1 mg/ml) (C, E, and H) or an equivalent concentration of CD alone or
xycholesterol (7bHC), 7-ketocholesterol (7KC), 19-hydroxycholesterol (19HC),
hydrocholesterol (7DHC), lathosterol, 24,25-dihydrolanosterol (24,25DHL), or
).
ntrations of Chol/CD (0–20 mg/ml) for 8 hr (n = 8). Total cellular cholesterol levels
are sometimes contained within the symbols.
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Figure 6. Insig and Scap Are Not Required for Accelerated Degradation of SM
(A) SRD-15 cells, deficient in Insig, were treated as in Figure 1D (n = 5, ± SEM).
(B) SRD-15 cells were treated as in Figure 5A. Cell lysates were assayed for SM by immunoblotting (n = 4).
(C) SRD-13A cells are deficient in Scap. The indicated cell lines were transfected with 1 mg of pTK-SM-V5, statin pretreated overnight, and treated in medium B
containing cycloheximide (10 mg/ml) with or without Chol/CD (20 mg/ml) for 8 hr. SM-V5 protein was analyzed by immunoblotting (each n = 2).
Cell Metabolism
Regulated Degradation of Squalene Monooxygenasethe first 100 amino acids of the full-length protein (data not
shown) and heterologous fusions (Figure S5E), which all retained
cholesterol-regulated turnover. These data suggest that a
specific regulated ubiquitination site may be unnecessary and/
or that ubiquitination may occur on the N-terminal amino group.
Our studies suggest that accelerated SM degradation in
response to cholesterol has functional consequences, by
contributing to flux control through the cholesterol synthesis
pathway. This is based on proteasomal inhibition reversing
sterol-dependent accumulation of squalene, evenwhen employ-
ing radiolabeled mevalonate (to bypass HMGR). Moreover,
cholesterol fails to accelerate degradation of the SM construct
lacking the N-terminal domain, with a concomitant greater flux
through SM (as indicated by increased formation of the productFigure 5. Regulated Turnover of SM Is Mediated by the Ubiquitin-Prot
(A) SRD-1 cells were statin pretreated overnight and treated in medium B contain
cated. Cell lysates were assayed for SM by immunoblotting (n = 3, ± SEM).
(B and C) CHO-7 cells were transfected with 1 mg of plasmid as indicated, statin
contain glycine-alanine repeats at the C and/or N termini of wild-type (WT) SM-V5
(D) CHO-7 cells (in 6 cm dishes) were transfected with 1.5 mg of pTK-SM-V5 and
mediumBwith or without Chol/CD (20 mg/ml) andMG132 (10 mM) as indicated. The
were assayed for SM-V5 or HA-ubiquitin by immunoblotting (n = 2).
(E–G) Statin pretreated SRD-1 (E and G) or CHO-7 (F) cells were treated in medium
[14C]-acetate (E) or [14C]-mevalonate (F and G) for 4 hr. [14C]-Squalene accumulati
1 (n = 4 in E, 5 in F, and 3 in G, +SEM).
See also Figure S4.
CeMOS). While generally comparable, the time course of squalene
accumulation did not exactly mirror falling SM protein levels
(cf. Figures 2B and 3A). However, it is noteworthy that in exper-
iments without cycloheximide, cholesterol-mediated effects on
the N-terminal domain were observed earlier (at 1 hr, with
ubiquitination [Figure S5G], and at 2 hr, with a pulse-chase
approach [Figure 7F]). This more rapid timing is compatible
with that observed for squalene accumulation (obtained without
cycloheximide). It is possible that cycloheximide may alter
the kinetics of SM degradation, as has been noted previously
for HMGR (Chun et al., 1990). Nevertheless, there is a chance
that other posttranscriptional mechanisms may be involved in
the control of mammalian SM activity, which remain to be
revealed.easome System
ing cycloheximide (10 mg/ml), Chol/CD (20 mg/ml), and MG132 (10 mM), as indi-
pretreated and treated as in (A) for 8 hr (n = 4 each). The SM constructs in (C)
as indicated. Cell lysates were assayed for SM-V5 by immunoblotting (n = 2).
0.5 mg of pMT123 (pUb-HA, HA-tagged ubiquitin), statin pretreated, treated in
SM-V5was immunoprecipitated from cell lysates. Immunoprecipitated pellets
A with or without Chol/CD (20 mg/ml) and/or MG132 (10 mM), and labeled with
on was expressed relative to themaximal condition (Chol/CD), which was set to
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Regulated Degradation of Squalene MonooxygenaseAlthough Chol/CD may be considered a nonphysiological
mode of cholesterol delivery, it was employed for most experi-
ments in this paper as it produced amore robust squalene accu-
mulation than LDL (illustrated in Figures 1A and 1B and Fig-
ure S1B). Furthermore, Chol/CD also offers advantages in that
is a far ‘‘cleaner’’ source of cholesterol than LDL (i.e., devoid
of other lipids) and delivers cholesterol directly, hence avoiding
the complications of having first to pass through the endo-
somal/lysosomal system. However, it should be noted that
increased SM degradation was observed in full serum compared
with cholesterol-depleted serum (Figure S2), consistent with the
physiological relevance of this mechanism.
In conclusion, our results suggest yet another layer of
complexity in the control of cholesterol synthesis. In an example
of end-product inhibition, cholesterol feeds back to stimulate the
proteasomal degradation of SM in a mechanism that is distinct
from that previously established for HMGR. This raises the
possibility that SM may constitute a second important control
point in cholesterol synthesis, serving as a reminder that flux
control of metabolic pathways tends to be shared by multiple
enzymes (Thomas and Fell, 1998), which could facilitate flexible
control of different intermediates. However, to what extent
degradation of SM normally regulates cholesterol synthesis
in vivo remains to be determined. Our findings may explain the
often observed positive association between serum levels of
squalene and cholesterol in humans, under a variety of patho-
physiological and pharmacological conditions (e.g., Rajaratnam
et al., 1999). Furthermore, our work may have important impli-
cations for human health and disease, notably in relation to
cardiovascular disease, but also other conditions (e.g., neurode-
generative diseases and certain cancers) in which cholesterol
has also been implicated. Moreover, this work may stimulate
interest in SM as a potential therapeutic target for cholesterol-
related diseases (Chugh et al., 2003).Figure 7. The N-Terminal Domain of Human SM Is Necessary and Suffi
(A) Multiple sequence alignment of the first 150 amino acids of SM for selected
(B) Schematic of SM deletion and fusion constructs.
(C, D, and E) CHO-7 cells were transfected as indicated. After statin pretreatmen
without Chol/CD (20 mg/ml), and/or MG132 (10 mM) for 8 hr. V5-tagged SM cons
(C) One microgram pTK-SM-V5 (WT) or pTK-SM-D(W2-K100)-V5 [D(W2-K100)] (n =
(D) Statin-pretreated CHO-7 cells transfected the previous day with 1 mg DNA as
Chol/CD (20 mg/ml) for 4 hr. Cells were assayed for accumulation of [14C]-cholest
band is indicated with an arrow. The [14C]-squalene to [14C]-MOS ratio was expre
treated with Chol/CD), which was set to 1. For the Chol/CD conditions, the D(W2
wild-type (WT) construct (p < 0.05 by t test; n = 5, +SEM).
(E) 0.5 mg pTK-SM-V5 (WT) and/or 0.5 mg pTK-SM-N100-GFP-V5 (N100-GFP) (n
(F) CHO-7 cells were transfected with 0.25 mg of pTK-SM-N100-GST-V5 (N100-G
cysteine and then chased in medium B with or without Chol/CD (20 mg/ml) for 0
analyzed by SDS-PAGE, and the band visualized by phosphorimaging. For the i
The –Chol/CD values, which did not change over the 8 hr, were each set to
(p < 0.05 by t test; n = 4, +SEM).
(G) CHO-7 cells (in 10 cm dishes) were transfected with 1.5 mg pTK-SM-N100-G
statin pretreatment, cells were treated in medium B with or without Chol/CD (20
glutathionine sepharose and immunoblotted for V5 (N100-GST) and HA-ubiquitin
(H) Segmental control of the mevalonate pathway. Sterol-dependent, posttrans
ubiquitin-proteasome system. 3-Hydroxy-3-methylglutaryl-coenzyme A reductas
oxysterols (not shown), which will consequently also reduce flux into the nonsterol
is accelerated by the end product, cholesterol itself, specifically inhibiting ste
N-terminal 100 amino acids, here designated as the regulatory domain (Reg.), w
See also Figure S5.
CeEXPERIMENTAL PROCEDURES
A complete description of materials, cell culture procedures and media (A–I),
primers, and other methods is available in the Supplemental Experimental
Procedures.
Cell Culture
In general, various CHO cell lines were employed (kind gifts of Goldstein,
Brown, and DeBose-Boyd, University of Texas Southwestern, Dallas). Unless
otherwise stated, cells were statin pretreated overnight (16 hr) to deplete
sterols through incubation in medium containing LPDS, the HMGR inhibitor
compactin (5 mm), and a low level of mevalonate (50 mm) that allows synthesis
of essential non-sterol isoprenoids but not of cholesterol (Hartman et al.,
2010). After statin pretreatment, cells were washed once with PBS, which
was sufficient to remove any residual compactin. For treatment, the media
was refreshed to include test agents as described in the figure legends for
the times indicated, followed by cell harvesting for the assays described
below.
Metabolic Labeling of Squalene and Cholesterol
Accumulation of [14C]-squalene and [14C]-cholesterol were determined by
radio-TLC (thin-layer chromatography) as described (Wong et al., 2008) with
minor modifications (see the Supplemental Experimental Procedures for
details). After statin pretreatment, cells were metabolically labeled with
1 mCi/well [14C]-acetate or [14C]-mevalonate added to the existing media for
the last 2 or 4 hr of treatment, as indicated. Cell lysates were subjected to alka-
line saponification followed by neutral lipid extraction. Bands corresponding to
authentic standards were visualized with a FLA-5100 phosphorimager (Fuji-
film), and their relative intensities were quantified with Sciencelab ImageGauge
4.0 Software (Fujifilm).
Quantitative Real-Time PCR
As previously described (Wong et al., 2008), RNA was harvested in triplicate
with TRIzol reagent and reverse transcribed to yield complementary DNA
(cDNA) with the SuperScript III First Strand cDNA Synthesis kit (Invitrogen),
and mRNA levels determined relative to the housekeeping gene by quantita-
tive real-time PCR using SYBR Green and a Corbett Rotorgene 3000. Primers
were directed against SM (SQLE) and HMGR (HMGCR), with porphobilinogen
deaminase (Pbgd) as the housekeeping gene.cient for Cholesterol-Dependent Proteasomal Degradation
species.
t, cells were treated in medium B containing cycloheximide (10 mg/ml), with or
tructs were analyzed by immunoblotting.
2).
in (C) were labeled with [14C]-acetate in medium A and treated with or without
erol, [14C]-squalene, and [14C]-2,3-monooxidosqualene (MOS). The [14C]-MOS
ssed relative to the maximal condition (cells transfected with pTK-SM-V5 and
-K100) construct produced a lower [
14C]-squalene to [14C]-MOS ratio than the
= 3).
ST). After statin pretreatment, cells were pulsed for 3 hr with [35S]-methionine/
–8 hr. [35S]-N100-GST protein was pulled down with glutathionine sepharose,
mage shown, densitometric values were plotted for the +Chol/CD conditions.
1. Right-hand panel: Cholesterol significantly degraded N100-GST at 2 hr
ST-V5 (N100-GST) and 0.5 mg pMT123 (pUb-HA, HA-tagged ubiquitin). After
mg/ml) and MG132 (10 mM) for 4 hr. N100-GST protein was pulled down with
(n = 2).
lational control of the mevalonate pathway is mediated in large part by the
e (HMGR) is degraded in response to 24,25-dihydrolanosterol and side-chain
branch of the pathway. In contrast, turnover of squalenemonooxygenase (SM)
rol production. This cholesterol-dependent degradation of SM requires its
hich is separate from the catalytic portion of the enzyme.
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Immunoblot analysis was performed as described (Kristiana et al., 2010) with
minor modifications. Cells were lyzed in 100 ml 10% (w/v) SDS with 5 ml
protease inhibitor cocktail. Samples (usually 40 mg of protein) were analyzed
by 10% SDS-PAGE and immunoblotted with the following antibodies:
anti-V5 (1:10000), anti-SM (1:5000), anti-HA (1:10000), and anti-a-tubulin
(1:200000). The observed endogenous protein bands migrated according to
their calculated molecular weight: 64 kDa for SM and 50 kDa for a-tubulin.
The relative intensities of bands were quantified by densitometry with ImageJ
Software (1.36b).
Transfection
CHO cells in 6-well plates (unless otherwise stated) were grown in medium A
(but without antibiotics) and transfected the following day with Lipofectamine
LTX reagent (Invitrogen) according to the manufacturer’s instructions, with
a ratio of 1 mg of DNA:4 ml of transfection reagent. DNA was equalized with
empty vector between different conditions. After 24 hr transfection, cells
were statin pretreated overnight and then treated as indicated.
Cholesterol Mass Determination
Cells were washed, harvested in modified RIPA buffer (1.0% IGEPAL CA-630,
0.1%SDS, 0.5% sodium deoxycholate, 1mM sodium orthovanadate, 150mM
NaCl, 1 mM Na EDTA, 20 mM Tris-HCl [pH 7.4]) and passed through an 18G
needle 20 times. Total cellular cholesterol content was determined using the
Amplex Red Cholesterol assay kit (Invitrogen), according to the manufac-
turer’s instructions (with an Fmax microplate spectrofluorometer [Molecular
Devices, CA], excitation l = 544 nm, emission l = 590 nm), and expressed rela-
tive to protein (measured by the Bicinchoninic Acid assay, Pierce).
Ubiquitination of Human SM
After transfection and treatment (as indicated in the figure legends), CHO-7
cells were lyzed in modified RIPA buffer (described above) supplemented
with N-ethylmaleimide (10 mM), protease inhibitor cocktail, and ALLN
(25 mg/ml). Lysates with equal cell protein were immunoprecipitated with
monoclonal anti-V5-conjugated Dynabeads (Invitrogen), according to the
manufacturer’s instructions. Pull-down of the N100-GST fusion protein from
lysates with equal cell protein was achieved using glutathione sepharose
beads. Pellets were subjected to 7.5% SDS-PAGE, followed by immunoblot
analysis with anti-V5 (for SM) and anti-HA (for ubiquitin) antibodies.
Metabolic Labeling of N100-GST with [35S]-Methionine/Cysteine
CHO-7 cells were transiently transfected as indicated in the figure legend.
After statin pretreatment, cells were labeled in methionine-free medium
(Invitrogen) supplemented with 5 mM compactin and 50 mM mevalonate con-
taining 250 mCi/ml [35S]-Protein Labeling Mix (Perkin Elmer) for 3 hr, then
washed and chased in medium B containing 2 mM methionine and cysteine
with or without Chol/CD, for 0–8 hr. [35S]-labeled N100-GST was pulled
down from lysates with equal cell protein using glutathione sepharose beads,
and pellets were subjected to 4%–20% or 10% SDS-PAGE. Bands were visu-
alized by phosphorimaging, and their relative intensities were quantified with
Sciencelab ImageGauge 4.0 Software (Fujifilm).
Data Presentation
Unlessotherwise indicated, valuesarenormalized to the vehicle-treated control
condition. Quantitative data are presented as averages and all error bars repre-
sent the standard error of the mean (SEM). Other data are comprised or repre-
sentative of at least n separate experiments, as noted in the figure legends.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at doi:10.1016/
j.cmet.2011.01.015.
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